TY - JOUR
T1 - Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
AU - de Joode, Karlijn
AU - Heersche, Niels
AU - Basak, Edwin A.
AU - Bins, Sander
AU - van der Veldt, Astrid A.M.
AU - van Schaik, Ron H.N.
AU - Mathijssen, Ron H.J.
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2024/1
Y1 - 2024/1
N2 - The development of immune checkpoint inhibitors (ICIs) has a tremendous effect on the treatment options for multiple types of cancer. Nonetheless, there is a large interpatient variability in response, survival, and the development of immune-related adverse events (irAEs). Pharmacogenetics is the general term for germline genetic variations, which may cause the observed interindividual differences in response or toxicity to treatment. These genetic variations can either be single-nucleotide polymorphisms (SNPs) or structural variants, such as gene deletions, amplifications or rearrangements. For ICIs, pharmacogenetic variation in the human leukocyte antigen molecules has also been studied with regard to treatment outcome. This review presents a summary of the literature regarding the pharmacogenetics of ICI treatment, discusses the most important known genetic variations and offers recommendations on the application of pharmacogenetics for ICI treatment.
AB - The development of immune checkpoint inhibitors (ICIs) has a tremendous effect on the treatment options for multiple types of cancer. Nonetheless, there is a large interpatient variability in response, survival, and the development of immune-related adverse events (irAEs). Pharmacogenetics is the general term for germline genetic variations, which may cause the observed interindividual differences in response or toxicity to treatment. These genetic variations can either be single-nucleotide polymorphisms (SNPs) or structural variants, such as gene deletions, amplifications or rearrangements. For ICIs, pharmacogenetic variation in the human leukocyte antigen molecules has also been studied with regard to treatment outcome. This review presents a summary of the literature regarding the pharmacogenetics of ICI treatment, discusses the most important known genetic variations and offers recommendations on the application of pharmacogenetics for ICI treatment.
UR - http://www.scopus.com/inward/record.url?scp=85178141284&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2023.102662
DO - 10.1016/j.ctrv.2023.102662
M3 - Review article
C2 - 38043396
AN - SCOPUS:85178141284
SN - 0305-7372
VL - 122
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
M1 - 102662
ER -